[This Week's IPO] Demand Forecast and Subscription Schedule for the First Week of May

In the first week of this month (May), CU Box, MonitorLab, and Proteomtech are scheduled to conduct demand forecasting for institutional investors.

◆CU Box= CU Box, established in 2010, is a company specializing in artificial intelligence video recognition, having developed various AI face recognition solutions and systems. It supplies AI systems to national security facilities such as airport automated immigration gates, the four major government buildings, and the National Information Resources Service, and is currently promoting the Incheon International Airport Smart Pass project. Additionally, since its full-scale entry into the private market in 2022, it has been providing face recognition-based identity verification solutions to various financial institutions' mobile applications.

The total number of shares offered is 1.5 million, with a desired offering price band of KRW 17,200 to KRW 23,200 per share, aiming to raise up to KRW 34.8 billion through this offering. Demand forecasting for institutional investors will be conducted from May 3 to 4 to finalize the offering price, followed by general subscription on the 9th and 10th. The company is expected to be listed in May. The lead underwriter is Shinhan Investment Corp., and the joint underwriter is SK Securities.

◆MonitorLab= MonitorLab is a cloud-based SECaaS (Security as a Service) platform company. SECaaS refers to cloud-based subscription security services. In 2016, MonitorLab launched AIONCLOUD, the first SECaaS platform in Korea, leading the domestic cloud security market.

The company plans to offer a total of 2 million shares, with a desired offering price range of KRW 7,500 to KRW 9,800. After demand forecasting on May 3 and 4, general investor subscription will take place over May 10 and 11. The listing underwriter is Mirae Asset Securities.

◆Proteomtech= Founded in 2000, Proteomtech is a specialized company developing and manufacturing in vitro diagnostic medical devices. It possesses proprietary immunodiagnostic technology, having succeeded in developing the world's largest allergy multiplex diagnostic kit, 'Protia Allergy Q-128M.' Unlike existing diagnostic products, Protia Allergy Q-128M applies parallel line-type array manufacturing technology, enabling simultaneous testing of 118 allergens with a minimal amount of serum.

The total number of shares offered is 2 million, with a desired offering price of KRW 7,500 to KRW 9,000, and a total offering amount between KRW 15 billion and KRW 18 billion. Institutional demand forecasting will be conducted from May 3 to 4 to finalize the offering price, followed by a two-day general investor subscription on May 10 and 11. The underwriter is Kiwoom Securities.

This content was produced with the assistance of AI translation services.